Moderna, Inc. — Form 10-Q
Filed July 31, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 18/100
What the filing says
Moderna amended its by-laws effective May 6, 2026, updating stockholder meeting procedures, proxy access nomination rules, director election mechanics, and indemnification provisions. Key changes include refined proxy access eligibility (3% ownership for 3 years, up to 20 stockholders), maximum stockholder nominees of 20% of board size, enhanced disclosure requirements for stockholder proposals, and strengthened indemnification for directors and officers. No financial impact stated; this is procedural/governance restructuring.
Why this rating
Pure governance amendment with no revenue, cost, or strategic business impact. Standard corporate housekeeping relative to $9.9B company.
See more from July 31, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.